Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research
Published in: Breast Cancer Research 2/2007

01-12-2007 | Short communication

Endocrine and targeted treatments for breast cancer

Author: Clifford A Hudis

Published in: Breast Cancer Research | Special Issue 2/2007

Login to get access

Excerpt

Endocrine therapy for breast cancer is arguably the first effective systemic treatment for human cancer and is the first targeted therapy [1]. Similar to many recently developed targeted therapies for breast and other malignancies, hormonal treatments for breast cancer include ligand deprivation (oestrogen depletion) and receptor agonism and antagonism. Given the safety and efficacy of the established hormonal options, the growing challenge that we confront with the development of an increasing number of novel targeted agents is whether these can be combined rationally, and if so then how, to improve patient outcomes while avoiding unwarranted toxicities. …
Literature
1.
Beatson GT: On the treatment of inoperable carcinoma of the mamma: suggestions for a new method of treatment, with illustrative cases. Lancet. 1896, ii: 104-107. 10.1016/S0140-6736(01)72307-0.CrossRef
2.
Cannellos GP, DeVita VT, Gold GL, Chabner BA, Schein PS, Young RC: Cyclical combination chemotherapy for advanced breast cancer. BMJ. 1974, 1: 218-220.CrossRef
3.
Sledge GW, Neuberg D, Bernardo P, Ingle JN, Martino S, Rowinsky EK, Wood WC: Phase III Trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: an Intergroup Trial (E1193). J Clin Oncol. 2003, 21: 588-592. 10.1200/JCO.2003.08.013.CrossRefPubMed
4.
Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, et al: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001, 344: 783-792. 10.1056/NEJM200103153441101.CrossRefPubMed
5.
6.
Dowsett M, Harper-Wynne C, Boeddinghaus I, Salter J, Hills M, Dixon M, Ebbs S, Gui G, Sacks N, Smith I: HER-2 amplification impedes the antiproliferative effects of hormone therapy in estrogen receptor-positive primary breast cancer. Cancer Res. 2001, 61: 8452-8458.PubMed
7.
Shou J, Massarweh S, Osborne CK, Wakeling AE, Ali S, Weiss H, Schiff R: Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer. J Natl Cancer Inst. 2004, 96: 926-935.CrossRefPubMed
8.
Kaufman B, Mackey J, Clemens M, Bapsy P, Vaid A, Wardley A, Tjulandin S, Jahn M, Lehle M, Jones A: Trastuzumab plus anastrozole prolongs progression-free survival in postmenopausal women with HER2-positive, hormone-dependent metastatic breast cancer (MBC). Proceedings from the 31st ESMO Congress, Istanbul. 2006, Abstract LBA2-
9.
Geyer CE, Forster J, Lindquist D, Chan S, Romieu CG, Pienkowski T, Jagiello-Gruszfeld A, Crown J, Chan A, Kaufman B, et al: Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med. 2006, 355: 2733-2743. 10.1056/NEJMoa064320.CrossRefPubMed
10.
Kurebayashi J, Okubo S, Yamamoto Y, Sonoo H: Inhibition of HER1 signaling pathway enhances antitumor effect of endocrine therapy in breast cancer. Breast Cancer. 2004, 11: 38-41.CrossRefPubMed
11.
Johnston SR, Head J, Pancholi S, Detre S, Martin LA, Smith IE, Dowsett M: Integration of signal transduction inhibitors with endocrine therapy: an approach to overcoming hormone resistance in breast cancer. Clin Cancer Res. 2003, 9: 524S-532S.PubMed
12.
Subbaramaiah K, Howe LR, Port ER, Brogi E, Liu CH, Hla T, Dannenberg AJ: Cox-2-derived prostaglandins regulate aromatase activity in breast cancer [abstract 1940]. Proceedings of the American Association for Cancer Research; 11–14 July 2003; Washington, DC. 2003, Philadelphia, PA: American Association for Cancer Research, 44-
13.
Subbaramaiah K, Howe LR, Port ER, Brogi E, Fishman J, Liu CH, Hla T, Hudis C, Dannenberg AJ: HER-2/neu status is a determinant of mammary aromatase activity in vivo: evidence for a cyclooxygenase-2-dependent mechanism. Cancer Res. 2006, 66: 5504-5511. 10.1158/0008-5472.CAN-05-4076.CrossRefPubMed
14.
Hanahan D, Folkman J: Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell. 1996, 86: 353-364. 10.1016/S0092-8674(00)80108-7.CrossRefPubMed
15.
Shweiki D, Itin A, Neufeld G, Gitay-Goren H, Keshet E: Patterns of expression of vascular endothelial growth factor (VEGF) and VEGF receptors in mice suggest a role in hormonally regulated angiogenesis. J Clin Invest. 1993, 91: 2235-2243. 10.1172/JCI116450.CrossRefPubMedPubMedCentral
16.
Albrecht ED, Aberdeen GW, Niklaus AL, Babischkin JS, Suresch DL, Pepe GJ: Acute temporal regulation of vascular endothelial growth/permeability factor expression and endothelial morphology in the baboon endometrium by ovarian steroids. J Clin Endocrinol Metab. 2003, 88: 2844-2852. 10.1210/jc.2002-021546.CrossRefPubMed
17.
Jain RK, Safabakhsh N, Sckell A, Chen Y, Jiang P, Benjamin L, Yuan F, Keshet E: Endothelial cell death, angiogenesis, and microvascular function after castration in an androgen-dependent tumor: role of vascular endothelial growth factor. Proc Natl Acad Sci USA. 1998, 95: 10820-10825. 10.1073/pnas.95.18.10820.CrossRefPubMedPubMedCentral
18.
Traina TA, Dickler MN, Caravelli JF, Yeh BM, Brogi E, Panageas K, Flores SA, Norton L, Hudis C, Rugo H: A phase II trial of letrozole in combination with bevacizumab, an anti-VEGF antibody, in patients with hormone receptor-positive metastatic breast cancer [abstract]. Breast Cancer Res Treat. 2005, 94 (Suppl 1): A2030-
Metadata
Title
Endocrine and targeted treatments for breast cancer
Author
Clifford A Hudis
Publication date
01-12-2007
Publisher
BioMed Central
Published in
Breast Cancer Research / Issue Special Issue 2/2007
Electronic ISSN: 1465-542X
DOI
https://doi.org/10.1186/bcr1823

Other articles of this Special Issue 2/2007

Breast Cancer Research 2/2007 Go to the issue

Short communication

Short-term presurgical treatment for all?

Short communication

Decision making in local therapy for breast cancer

Short communication

Benefits of complementary therapies

Short communication

Why patient representation might harm science?

Short communication

Metabolic approaches to breast cancer treatment and prevention

Short communication

Why patient recorded outcomes should be mandatory in and outside clinical trials to guide management of patients with metastatic breast cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits